Clinical pharmacology of carboplatin.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Seminars in Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 2200133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

  1987cited by this paper
• Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

  1985cited by this paper
• Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.

  1984cited by this paper
• Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.

  1984cited by this paper
• A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).

  1983cited by this paper

• Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

  2019cites this paper
• Neurological Complications of Chemotherapy

  2018cites this paper
• DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing.

  2017cites this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

  2017cites this paper
• Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs

  2015cites this paper
• Liposomes, a promising strategy for clinical application of platinum derivatives

  2013cites this paper
• Neurologic Complications of Chemotherapy

  2008cites this paper
• The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review.

  2006cites this paper
• Alkylating and Platinating Agents

  2001cites this paper
• Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.

  1999cites this paper
• Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

  1999cites this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cites this paper
• Evaluation of Equations for Carboplatin Dosage

  1995cites this paper
• Ototoxicity of chemotherapeutic agents.

  1993cites this paper
• Cisplatin‐induced platelet activation requires mononuclear cells: role of GMP‐140 and modulation of procoagulant activity

  1993cites this paper
• Carboplatin in combination as first-line therapy in advanced breast cancer.

  1993cites this paper
• Carboplatin, vinblastine and mitomycin-C in the treatment of non-small cell bronchogenic carcinoma.

  1992cites this paper
• La chemioterapia endoarteriosa dei tumori cerebrali con Carboplatino

  1992cites this paper
• Non small cell lung cancer treatment with carboplatin and vindesine: a phase II study.

  1992cites this paper